Bone Disease and HIV Infection
30th Nov 2005, 19:24 GMT
The high prevalence of bone demineralization among human immunodeficiency virus (HIV)–infected patients in the current therapeutic era has been described in multiple studies, sounding the alarm that we may expect an epidemic of fragility fractures in the future. However, despite noting high overall prevalences of osteopenia and osteoporosis, recent longitudinal studies that we review here have generally not observed accelerated bone loss during antiretroviral therapy beyond the initial period after treatment initiation. We discuss the continued progress toward understanding the mechanisms of HIV-associated bone loss, particularly the effects of HIV infection, antiretroviral therapy, and host immune factors on bone turnover. We summarize results of clinical trials published in the past year that studied the safety and efficacy of treatment of bone loss in HIV-infected patients and provide provisional opinions about who should be considered for bone disease screening and treatment.
Bone Disease and HIV Infection related news:
- Volume 42, number 1: Bone Disease and HIV Infection — Clin Infect Dis Latest Issue
- Dyslipidaemia and cardiovascular risk in HIV infection — Medscape Internal Medicine Headlines
- Less Fear of HIV is Pushing up Infection Rates Among Gay Men — DW-WORLD.DE Top Stories
- Kenya: Kenya's HIV Infection Rate Declines — AllAfrica News: Health and Medicine
- Volume 42, number 1: Parasitic Central Nervous System Infections in Immunocompromised Hosts: Malaria, Microsporidiosis, Leishmaniasis, and African Trypanosomiasis — Clin Infect Dis Latest Issue
- PEP reduces risk of HIV infection — KeralaNext: Health
- Loving Without Fear of HIV — Real & Revealing
- Hungary registers 99 cases of HIV infection in first nine months — People's Daily Online
- Russia's First HIV Patient Tells Story of Alienation and Persecution — MosNews.com RSS
- WHO: Lesotho launches groundbreaking HIV campaign on World AIDS Day — noticias.info
Latest news from Clin Infect Dis Latest Articles:
- Clinical Reevaluation of the QuantiFERON TB-2G Test as a Diagnostic Method for Differentiating Active Tuberculosis from Nontuberculous Mycobacteriosis
- Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor-Containing Antiretroviral Combination to a 3-Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir